The effect of magnesium sulfate loading dose in treatment of diabetic ketoacidosis
Phase 3
- Conditions
- Diabetic ketoacidosis.Diabetes mellitus due to underlying condition with ketoacidosisE08.1
- Registration Number
- IRCT20220928056051N3
- Lead Sponsor
- Oroumia University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Patients with diabetic ketoacidosis
Age between 14-65 years
Exclusion Criteria
Hypermagnesemia (magnesium more than 3 mg/dL)
Hypomagnesemia (magnesium less than 1.5 mg/dL)
Having clinical symptoms of hypermagnesemia including neuromuscular symptoms (loss of deep tendon reflexes, muscle paralysis, apnea) and cardiovascular symptoms
Severe renal failure (GFR < 30 ml/min/1.73 m2)
Patients with drug poisoning
Pregnancy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The total dose of prescribed insulin until the patient exits from acute phase of diabetic ketoacidosis. Timepoint: Daily until the third day after the intervention. Method of measurement: Vial.;The total dose of prescribed potassium until the patient exits from acute phase of diabetic ketoacidosis. Timepoint: Daily until the third day after the intervention. Method of measurement: Vial.;The length of time it will take time to convert insulin administration from IV to subcutaneous form. Timepoint: Until the third day after the intervention. Method of measurement: Clock.
- Secondary Outcome Measures
Name Time Method Prolonged time for patient recovery from acute phase of diabetic ketoacidosis. Timepoint: Until the third day after the intervention. Method of measurement: Clock.;Serum magnesium. Timepoint: Before and daily until the third day after the intervention. Method of measurement: Blood test.;Fasting blood sugar. Timepoint: Before and daily until the third day after the intervention. Method of measurement: Blood test.